Joining AI Drug Discovery Race, Erasca Adds $22M For Cancer Work

Erasca, a biotech startup run by the former CEO of Ignyta, debuted in December with $42 million and an audacious plan to ?erase cancer,? but provided little explanation as to how. Erasca is still keeping many of those details under wraps. But Jonathan Lim, the company?s co-founder and executive chairman, this week outlined, at least [?]